ARTICLE | Product Development
Celcuity’s breast cancer data show broad PI3K pathway blockade can deliver
Also in BioCentury’s clinical report: an Alzheimer’s update from Roche, and more
July 29, 2025 10:34 PM UTC
Celcuity posted the biggest data-driven stock gain of the week after reporting combination therapies containing multi-kinase inhibitor gedatolisib improved progression-free survival in HR+/HER2- advanced breast cancer patients lacking PIK3CA mutations.
On Monday, Celcuity Inc. (NASDAQ:CELC) reported placebo-adjusted PFS gains of 7.3 months and 5.4 months with a gedatolisib-containing triplet therapy and doublet therapy, respectively, in the PIK3CA wild-type cohort of the Phase III VIKTORIA-1 study. ...